Danaher Corporation

DHR · Healthcare

$219.81
+1.08% today

What a holder would want to know before buying DHR: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.

Where the price sits
Low $161.91 · May 2026High $242.05 · Jan 2026

Today’s price is 36% above the lowest point of the past year and 9% below the highest.

Over the past year it was cheaper than today on 74% of days and more expensive on 26%. Over the last 10 years: cheaper on 67% of days.

9% above its average price of the last 200 trading days.

How bad does it get

Fell 20% or more twice in 10 years. The deepest fall was 45%; the longest took 3 months to get back to its peak. 1 of 2 have recovered so far.

It is in one now: 25% below the Sep 2021 peak.

Sep 2021
−45%not back yet
Jan 2020
−28%back in 3 months
What you own

Danaher Corporation · Healthcare · Diagnostics & Research · a large company worth $154.52B

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology,…

Is it making money?
2022
2023
2024
2025

revenue profit

Sales of $24.57B in 2025, with $3.61B of profit. Sales grew in 1 of the last 3 years.

Keeps about 16 cents of every dollar of sales as profit.

Is it healthy?
Cash
$4.35B
Debt
$27.86B
Free cash flow / yr
$4.33B

Would need about 6.4 years of free cash flow to repay all its debt.

Is it expensive?

You pay $39 for every $1 of last year’s profit, and $24 for every $1 of profit expected next year.

A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.

Pays 0.74% a year in dividends at today’s price · next ex-dividend Sep 30.

What others are doing

25 analysts: 22 say buy, 3 hold, 0 sell. Their average 12-month target is $241.00 (range $200.00–$310.00).

Insiders made 0 purchases and 2 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.

Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.

Now try it without risking anything

Poshkan is paper trading: real prices, virtual money. Buy DHR with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.

Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.